- Halo Pharma is adding a Gerteis Macro-Pactor® roller compactor to its Whippany, New Jersey facility to expand dry-granulation and solid dose manufacturing capabilities.
- The equipment is expected to be operational in the first quarter of 2026 and is intended to support scale-up from development through to commercial manufacturing.
Halo Pharma has announced an expansion of its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor® roller compactor. The company operates as a CDMO providing pharmaceutical development and contract manufacturing services, with a focus on solid oral dose products.
The new equipment will complement the Gerteis Mini-Pactor® currently used at the site for development, clinical and small-scale commercial manufacturing. According to the company, the Macro-Pactor® is designed to enable a more direct scale-up path from early development to larger batch sizes, supporting both development and commercial programmes.
Halo Pharma said the Macro-Pactor® is expected to be online in the first quarter of 2026. The system is intended to increase throughput and expand dry-granulation capabilities, with applications including moisture-sensitive active pharmaceutical ingredients, high drug-load formulations, poor-flowing powders, potent compounds and modified-release products.
“One of the major advantages of adding the Macro-Pactor is that the process parameters established during early-phase development translates almost directly into larger batch sizes.”
Satish Shetty, Senior Director, Product Development & Technical Services at Halo Pharma
The company added that the closed, dust-contained design of the equipment supports safer and more controlled handling, while its data-driven process control is intended to support technology transfer and Quality by Design approaches. Halo Pharma said the investment aligns with its strategy to support clients from development through to commercial manufacturing at its Whippany site.
